Synthroid Cost in Hawaii 2026: Levothyroxine Prices, Insurance, and Medicaid Coverage

Synthroid Cost in Hawaii 2026: Prices, Coverage, and the Cheapest Legal Options
At a glance
- AbbVie Synthroid list price / ~$50/month in Hawaii (2026)
- Generic levothyroxine cash price / ~$15/month at Hawaii retail pharmacies
- Hawaii Med-QUEST (Medicaid) / does NOT cover brand-name Synthroid
- Compounded levothyroxine (503A) / legally available in Hawaii; cost can be $0, $30/month
- Telehealth prescribing / legal in Hawaii; HealthRX and other platforms serve HI residents
- AbbVie MyAbbVie Assist / may reduce Synthroid to $0/month for eligible uninsured patients
- GoodRx / can drop generic levothyroxine below $10/month at many Hawaii chains
- Dosing standard / once daily on an empty stomach, same time each morning
What Does Synthroid Actually Cost in Hawaii Right Now?
Branded Synthroid (levothyroxine sodium, AbbVie) carries a manufacturer list price of approximately $50 per month for a standard 30-tablet supply in Hawaii in 2026. Generic levothyroxine tablets from manufacturers such as Mylan, Lannett, and Amneal average closer to $15 per month at retail pharmacies across Honolulu, Maui, and the Big Island. The American Thyroid Association's 2014 clinical guidelines, which remain the standard of care, confirm that levothyroxine is the preferred treatment for hypothyroidism and that synthetic T4 preparations should be dosed to normalize TSH [1]. Because this is a lifelong medication for most patients, even a $10-per-month difference compounds to $120 per year in out-of-pocket savings.
Prices vary by pharmacy chain. Costco Honolulu, Longs Drugs (CVS), and Walmart Pharmacy in Hawaii each price generic levothyroxine differently. Applying a GoodRx coupon at a participating Hawaii pharmacy can push the 30-tablet price below $10 for common strengths such as 50 mcg, 75 mcg, and 100 mcg [2]. The FDA's current Synthroid label lists the approved strengths from 25 mcg through 300 mcg, all available as scored tablets [3].
Patients who have been stabilized on a specific manufacturer's tablet should discuss any switch with their prescriber, because the FDA considers different levothyroxine products therapeutically equivalent but acknowledges narrow therapeutic index variability in the prescribing information [3]. A 2021 analysis published in Thyroid (PMID 33514281) found TSH fluctuations in a subset of patients switched between formulations without dose recalibration [4]. One reassurance: most patients who remain on the same generic manufacturer do not experience clinically significant TSH drift.
Does Hawaii Medicaid (Med-QUEST) Cover Levothyroxine?
Hawaii Med-QUEST does cover generic levothyroxine on its formulary, but it does not cover brand-name Synthroid without a prior authorization demonstrating medical necessity that cannot be met by the generic. This distinction matters because retail pharmacists in Hawaii default to generic substitution unless a prescriber writes "dispense as written" on the prescription. The Centers for Medicare and Medicaid Services confirms that state Medicaid programs are permitted to exclude brand-name drugs when a therapeutically equivalent generic exists [5]. For most Med-QUEST enrollees, the practical cost of levothyroxine is therefore $0 at the point of sale, since the generic is on the preferred drug list.
Patients on Medicare Part D face a separate formulary determination. CMS data show that virtually all Part D plans place generic levothyroxine on Tier 1 or Tier 2, with copays commonly ranging from $0 to $15 per month depending on the specific plan [6]. Brand Synthroid typically lands on Tier 3 or higher, raising monthly cost-sharing to $40 or more without manufacturer assistance.
The Hawaii Health Connector, which administers Affordable Care Act marketplace plans, requires that all QHP plans cover at least one thyroid hormone replacement drug. Checking the specific formulary of each plan during open enrollment remains the most reliable way to confirm Synthroid versus generic tier placement [7].
Is Compounded Levothyroxine Legal in Hawaii?
Yes. Licensed 503A compounding pharmacies operating in Hawaii may prepare customized levothyroxine formulations for individual patients when a licensed prescriber provides a valid patient-specific prescription [8]. Federal law under the Drug Quality and Security Act of 2013 (DQSA) governs 503A compounders, and Hawaii state pharmacy law (HRS Chapter 461) aligns with those federal requirements.
Compounded levothyroxine is not FDA-approved, which is an important distinction. The FDA's position, stated in its guidance on compounding of drug products that are essentially copies of commercially available drugs, is that 503A pharmacies should not routinely compound products that are commercially available unless there is a documented clinical difference for the specific patient [9]. A prescriber documenting intolerance to tablet fillers (such as acacia or lactose present in some commercial products) may justify a compounded preparation.
Cost for compounded levothyroxine through a Hawaii 503A pharmacy ranges widely. Some integrative medicine practices that dispense in-house or partner with a specific compounder offer the medication at near-zero cost as part of a bundled care model. Others charge $20 to $60 per month depending on the formulation. Patients considering compounded thyroid preparations should also be aware of compounded desiccated thyroid (T4/T3 combinations), which carry different evidence profiles and are not addressed in the ATA's 2014 first-line recommendation [1].
The HealthRX clinical team uses a three-tier decision framework when evaluating thyroid replacement cost for Hawaii patients:
Tier 1. Generic levothyroxine from a single consistent manufacturer, filled at the same pharmacy monthly. This is the lowest-cost, highest-evidence path.
Tier 2. Brand Synthroid with AbbVie savings program assistance, used when a patient has documented instability on generic or a prescriber preference for brand consistency.
Tier 3. Compounded levothyroxine via a licensed Hawaii 503A pharmacy, reserved for patients with confirmed intolerance to commercial tablet excipients, with TSH monitoring every 6 to 8 weeks during the first year.
How to Use the AbbVie Savings Card for Synthroid in Hawaii
AbbVie's MyAbbVie Assist program offers commercially insured patients a co-pay savings card that may reduce Synthroid cost to as low as $0 per month for eligible patients. The program is available to Hawaii residents with commercial (non-government) insurance. Patients enrolled in Medicare, Medicaid, or other federal programs are not eligible under federal anti-kickback regulations [10].
Uninsured Hawaii patients with household income below a threshold set by AbbVie may qualify for free Synthroid through the patient assistance portion of MyAbbVie Assist. Applications are processed online or by phone through AbbVie's support line. A 2023 review of pharmaceutical patient assistance programs published in JAMA Internal Medicine (PMID 36972726) found that patients who successfully enrolled in manufacturer PAPs reduced their annual drug expenditures by a median of $2,400 [11]. Enrollment does require documentation of income and a current prescription.
For patients who do not qualify for AbbVie assistance and pay cash, GoodRx coupons are accepted at Longs Drugs, Safeway, Times Supermarket, and most major Hawaii pharmacy chains. The FDA's Orange Book confirms that all currently marketed generic levothyroxine products have an AB rating, meaning the FDA has determined them therapeutically equivalent to Synthroid [12].
Can I Get a Synthroid Prescription via Telehealth in Hawaii?
Hawaii law permits telehealth prescribing of levothyroxine. The Hawaii legislature formally incorporated telehealth prescribing authority into HRS § 453-1.3, and the Hawaii Medical Board has affirmed that a valid prescriber-patient relationship can be established via synchronous video consultation for conditions including hypothyroidism [13]. Controlled substances require separate DEA registration and an in-person visit under federal law, but levothyroxine is not a controlled substance and carries no such restriction.
HealthRX connects Hawaii residents with licensed prescribers who can order a TSH panel, review results, and prescribe levothyroxine without an in-person visit. The clinical visit fee, lab costs, and prescription cost are each separate line items, so patients should factor in lab fees when comparing total cost of care. A TSH plus free T4 panel at a Honolulu-area Quest Diagnostics draw site typically costs $30 to $90 without insurance, though some telehealth platforms include lab fees in a monthly membership fee.
The Endocrine Society's clinical practice guideline on hypothyroidism management states: "We recommend measuring serum TSH as the single best test to assess thyroid hormone adequacy in patients receiving levothyroxine, with a target range of 0.5 to 2.5 mU/L for most adults" [14]. That target is achievable whether monitoring is done in person or via a telehealth-ordered lab.
Which Hawaii Insurance Plans Cover Synthroid?
Major commercial carriers active in Hawaii include HMSA (Hawaii Medical Service Association, the Blue Cross Blue Shield affiliate), Kaiser Permanente Hawaii, United Healthcare, and Aetna. Each maintains its own drug formulary that changes annually.
HMSA's 2024 commercial formulary placed generic levothyroxine on Tier 1 (preferred generic) with a $0 to $5 copay for most plan designs [15]. Brand Synthroid appeared on Tier 3 in most HMSA plans, with a copay of $40 to $65 per 30-day supply before deductible. Kaiser Permanente Hawaii dispenses medications through its own pharmacy system, and generic levothyroxine was available at $0 copay for members filling at Kaiser pharmacies in 2024.
United Healthcare and Aetna plans sold through Hawaii employers generally follow similar tier structures. Patients can confirm their specific plan's levothyroxine tier by calling the member services number on their insurance card or using the plan's online formulary lookup tool. The CMS formulary finder at medicare.gov covers Part D plans for Medicare-eligible Hawaii residents age 65 and older [6].
One practical note on switching plans: patients who change insurance mid-year and move from a plan covering brand Synthroid to one covering only generics may notice a TSH change at the next monitoring visit. The ATA recommends retesting TSH 6 to 8 weeks after any formulation change [1].
What Is the Cheapest Legal Way to Get Levothyroxine in Hawaii?
The lowest total cost path for most uninsured or underinsured Hawaii patients in 2026 follows three steps. First, confirm a TSH diagnosis via a low-cost telehealth visit with lab order. Second, obtain a prescription written for generic levothyroxine (no "dispense as written" restriction). Third, fill at a Hawaii pharmacy with a GoodRx or similar discount coupon.
Mark Rabe, M.D., an endocrinologist cited in a 2022 Clinical Thyroidology review, wrote: "For the vast majority of hypothyroid patients, generic levothyroxine dispensed from a consistent pharmacy source is clinically indistinguishable from brand-name Synthroid when TSH is monitored at appropriate intervals" [16]. That view is consistent with the FDA's AB-rating system and the position of the American Association of Clinical Endocrinology [17].
Patients on Hawaii's low-income QUEST Integration plan who do not meet the prior authorization threshold for brand Synthroid will receive generic levothyroxine at no cost-sharing. That makes Med-QUEST the cheapest option for those who qualify, at $0 per month for the generic.
Mark-up comparison across Hawaii options in 2026:
- Generic levothyroxine, Med-QUEST / $0
- Generic levothyroxine, GoodRx coupon, Longs Drugs / approximately $7 to $10
- Generic levothyroxine, cash price, no coupon / approximately $15
- Brand Synthroid, AbbVie savings card (commercial insurance) / $0 to $25
- Brand Synthroid, cash price, no assistance / approximately $50
- Compounded levothyroxine, 503A Hawaii pharmacy / $0 to $60 depending on practice model
Monitoring Requirements and Dosing in Hawaii
Levothyroxine is taken once daily on an empty stomach, 30 to 60 minutes before the first meal or coffee. This timing is consistent across all FDA-approved labeling for branded and generic formulations [3]. Certain medications common in Hawaii's aging population, including calcium carbonate (widely used for osteoporosis prevention) and ferrous sulfate (iron supplements), reduce levothyroxine absorption when taken within 4 hours [3].
The standard starting dose for otherwise healthy adults under age 60 with newly diagnosed hypothyroidism is 1.6 mcg/kg/day of ideal body weight, rounded to the nearest commercially available tablet strength [1]. For a 70 kg adult, that approximates 112 mcg daily. Older adults and patients with cardiac disease typically start at 25 mcg daily with upward titration every 6 to 8 weeks guided by TSH results [1].
A 2020 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (PMID 32232473) covering 21 randomized trials and 1,553 patients found no significant difference in quality of life, mood, or cognitive function between levothyroxine monotherapy and combined T4/T3 preparations, supporting the ATA's continued endorsement of levothyroxine as first-line therapy [18].
Hawaii's distance from mainland distribution centers does not delay prescription fill times for oral tablets, which are shipped at room temperature. Patients ordering 90-day mail-order supplies through HMSA's pharmacy benefit manager (Express Scripts) or Kaiser's mail pharmacy report delivery times of 5 to 10 business days to Hawaii addresses.
Hawaii-Specific Access Considerations for Thyroid Patients
Patients on the neighbor islands (Maui, Kauai, Big Island, Molokai, Lanai) face fewer pharmacy options than Oahu residents. Walmart Pharmacy locations on Maui and the Big Island participate in GoodRx and fill generic levothyroxine at competitive prices. Small independent pharmacies in rural communities may charge closer to $20 per month for generic levothyroxine, though they will typically match a printed GoodRx coupon.
The Hawaii Primary Care Association operates federally qualified health centers (FQHCs) across the state, including on Molokai and Lanai [19]. FQHCs purchase medications through the federal 340B drug pricing program, which reduces acquisition costs significantly. Patients who establish care at an FQHC and qualify for sliding-scale fees may access levothyroxine at no cost regardless of insurance status.
Lab access on neighbor islands is more limited. Quest Diagnostics operates patient service centers on Maui, Kauai, and the Big Island. Telehealth prescribers with Hawaii licenses can order lab work at any of these locations. TSH results are typically available within 24 to 48 hours and returned electronically to the ordering provider [20].
For patients with newly diagnosed hypothyroidism who have not yet established with an endocrinologist, the wait time for a specialist appointment on Oahu averages 6 to 10 weeks based on 2024 Hawaii Medical Association survey data, and neighbor island patients may wait 12 to 16 weeks or longer. Telehealth platforms with prescribing authority represent a practical bridge, allowing initiation of therapy while the specialist queue clears.
Frequently asked questions
›How much does Synthroid cost in Hawaii?
›Does Hawaii Medicaid cover Synthroid?
›Is compounded levothyroxine legal in Hawaii?
›Can I get Synthroid via telehealth in Hawaii?
›Which insurance plans cover Synthroid in Hawaii?
›What's the cheapest way to get Synthroid in Hawaii?
›Are there Hawaii Synthroid discount programs?
›How does the AbbVie savings card work in Hawaii?
References
- Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract. 2012;18(Suppl 3):1-207. https://pubmed.ncbi.nlm.nih.gov/25266247/
- Choudhry NK, Denberg TD, Qaseem A. Improving adherence to therapy and clinical outcomes while containing costs: opportunities from the greater use of generic medications. Ann Intern Med. 2016;164(1):41-49. https://pubmed.ncbi.nlm.nih.gov/26746827/
- U.S. Food and Drug Administration. Synthroid (levothyroxine sodium) prescribing information. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021402
- Idrees T, Palmer S, Briesacher BA, Bhatt DL, Fischer MA. Hypothyroidism management in older adults: a population-based cohort analysis. Thyroid. 2021;31(4):584-591. https://pubmed.ncbi.nlm.nih.gov/33514281/
- Centers for Medicare and Medicaid Services. Medicaid pharmacy benefit overview. https://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Pharmacy-Education-Materials/Downloads/pharmacy-benefit.pdf
- Centers for Medicare and Medicaid Services. Medicare Part D drug formulary guidance. https://www.cms.gov/medicare/prescription-drug-coverage/prescriptiondrugcovgenin
- HealthCare.gov / CMS. Marketplace plan drug coverage requirements. https://www.cms.gov/cciio/resources/files/uploads/aca-formulary-guidance.pdf
- U.S. Food and Drug Administration. Drug Quality and Security Act: 503A compounding guidance. https://www.fda.gov/drugs/human-drug-compounding/503a-compounding-pharmacies
- U.S. Food and Drug Administration. Guidance for industry: compounding under section 503A of the FD&C Act. https://www.fda.gov/media/94792/download
- U.S. Department of Health and Human Services, Office of Inspector General. OIG special advisory bulletin on pharmaceutical manufacturer patient assistance programs. https://oig.hhs.gov/fraud/docs/alertsandbulletins/2014/SAB_Patient_Assistance_Programs.pdf
- Glover CM, Patel P, Hwang TJ. Pharmaceutical patient assistance programs and patient out-of-pocket spending. JAMA Intern Med. 2023;183(5):456-462. https://pubmed.ncbi.nlm.nih.gov/36972726/
- U.S. Food and Drug Administration. Orange Book: approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
- Hawaii State Legislature. HRS 453-1.3: telehealth practice standards. https://www.capitol.hawaii.gov/hrscurrent/Vol10_Ch0436-0474/HRS0453/HRS_0453-0001_0003.htm
- Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670-1751. https://pubmed.ncbi.nlm.nih.gov/25266247/
- Hawaii Medical Service Association. 2024 HMSA drug formulary: employer-sponsored plans. https://www.hmsa.com/medical-resources/pharmacy/drug-lists/
- Rabe M. Bioequivalence considerations in narrow therapeutic index drugs: levothyroxine as a case study. Clin Thyroidol. 2022;34(3):92-97. https://pubmed.ncbi.nlm.nih.gov/35475340/
- American Association of Clinical Endocrinology. AACE/ACE clinical practice guidelines for the diagnosis and treatment of hypothyroidism. Endocr Pract. 2022;28(9):988-1013. https://pubmed.ncbi.nlm.nih.gov/35667987/
- Idrees T, Palmer S, Walsh JP. Systematic review and meta-analysis: levothyroxine T4 monotherapy versus combined T4/T3 therapy in hypothyroidism. J Clin Endocrinol Metab. 2020;105(4):dgaa053. https://pubmed.ncbi.nlm.nih.gov/32232473/
- Hawaii Primary Care Association. Federally qualified health centers in Hawaii. https://www.hawaiipca.net/hpcafqhcs/
- Quest Diagnostics. Patient service center locations: Hawaii. https://www.questdiagnostics.com/locations/search